NPCE Quote, Financials, Valuation and Earnings

Butterfly Network has a net margin of -24.46% compared to NeuroPace's net margin of -80.99%. NeuroPace's return on equity of -216.38% beat Butterfly Network's return on equity of -37.41%.

NeuroPace has a consensus price target of $17.57, signalling upside risk potential of 63.66%. On the other hand Butterfly Network has an analysts' consensus of $5.00 which suggests that it could grow by 86.57%. Given that Butterfly Network has higher upside potential than NeuroPace, analysts believe Butterfly Network is more attractive than NeuroPace.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Butterfly Network has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Butterfly Network offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Butterfly Network pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are smaller than Butterfly Network quarterly revenues of $22.4M. NeuroPace's net income of -$5.3M is higher than Butterfly Network's net income of -$18.1M. Notably, NeuroPace's price-to-earnings ratio is -- while Butterfly Network's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.91x versus 6.91x for Butterfly Network. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -24.46% compared to NeuroPace's net margin of -370.29%. NeuroPace's return on equity of -216.38% beat Intelligent Bio Solutions's return on equity of -164.63%.

NeuroPace has a consensus price target of $17.57, signalling upside risk potential of 63.66%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 458.14%. Given that Intelligent Bio Solutions has higher upside potential than NeuroPace, analysts believe Intelligent Bio Solutions is more attractive than NeuroPace.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are larger than Intelligent Bio Solutions quarterly revenues of $607.5K. NeuroPace's net income of -$5.3M is lower than Intelligent Bio Solutions's net income of -$2.2M. Notably, NeuroPace's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.91x versus 2.46x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -24.46% compared to NeuroPace's net margin of -72.93%. NeuroPace's return on equity of -216.38% beat Standard BioTools's return on equity of -36.54%.

NeuroPace has a consensus price target of $17.57, signalling upside risk potential of 63.66%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 108.33%. Given that Standard BioTools has higher upside potential than NeuroPace, analysts believe Standard BioTools is more attractive than NeuroPace.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.11%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are smaller than Standard BioTools quarterly revenues of $46.7M. NeuroPace's net income of -$5.3M is higher than Standard BioTools's net income of -$34.1M. Notably, NeuroPace's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.91x versus 2.31x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -24.46% compared to NeuroPace's net margin of -111.78%. NeuroPace's return on equity of -216.38% beat LENSAR's return on equity of -134.77%.

NeuroPace has a consensus price target of $17.57, signalling upside risk potential of 63.66%. On the other hand LENSAR has an analysts' consensus of $13.00 which suggests that it could grow by 2.45%. Given that NeuroPace has higher upside potential than LENSAR, analysts believe NeuroPace is more attractive than LENSAR.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are larger than LENSAR quarterly revenues of $16.7M. NeuroPace's net income of -$5.3M is higher than LENSAR's net income of -$18.7M. Notably, NeuroPace's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.91x versus 3.26x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.